Evidence map›Paper›PMID 39204384›Full record

ArticlePharmaceutics2024

New Approaches for Basophil Activation Tests Employing Dendrimeric Antigen-Silica Nanoparticle Composites.

Silvia Calvo-Serrano, Esther Matamoros, Jose Antonio Céspedes, Rubén Fernández-Santamaría, Violeta Gil-Ocaña, Ezequiel Perez-Inestrosa, Cecilia Frecha, Maria I Montañez, Yolanda Vida, Cristobalina Mayorga and 1 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Silvia Calvo-SerranoAllergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.
Esther MatamorosDepartamento de Química Orgánica, Universidad de Málaga, Campus Teatinos s/n, 29071 Málaga, Spain.
Jose Antonio CéspedesAllergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.ORCID 0000-0002-3318-3689
Rubén Fernández-SantamaríaAllergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.ORCID 0000-0002-0255-4280
Violeta Gil-OcañaDepartamento de Química Orgánica, Universidad de Málaga, Campus Teatinos s/n, 29071 Málaga, Spain.
Ezequiel Perez-InestrosaDepartamento de Química Orgánica, Universidad de Málaga, Campus Teatinos s/n, 29071 Málaga, Spain.ORCID 0000-0001-7546-5273
Cecilia FrechaAllergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.
Maria I MontañezAllergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.ORCID 0000-0001-6641-5979
Yolanda VidaDepartamento de Química Orgánica, Universidad de Málaga, Campus Teatinos s/n, 29071 Málaga, Spain.
Cristobalina MayorgaAllergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.
Maria J TorresAllergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Parque Tecnológico de Andalucía, 29590 Málaga, Spain.

Funding

This work was supported by the Spanish Ministerio de Ciencia e Innovación (Proyectos de I+D+I «Programación Conjunta Internacional», EuroNanoMed 2019 (PCI2019-111825-2), Minis-terio de Ciencia e Innovación (PID2022-136705NB-I00, CNS2022-136144), Instituto This work was supported by the Spanish Ministerio de Ciencia e Innovación (Proyectos de I+D+I «Programación Conjunta Internacional», EuroNanoMed 2019 (PCI2019-111825-2), Minis-terio de Ciencia e Innovación (PID2022-136705NB-I00, CNS2022-136144), Instituto
6 · The paper itself

Abstract

In vitro cell activation through specific IgE bound to high-affinity receptors on the basophil surface is a widely used strategy for the evaluation of IgE-mediated immediate hypersensitivity reactions to betalactams. Cellular activation requires drug conjugation to a protein to form a large enough structure displaying a certain distance between haptens to allow the cross-linking of two IgE antibodies bound to the basophil's surface, triggering their degranulation. However, no information about the size and composition of these conjugates is available. Routine in vitro diagnosis using the basophil activation test uses free amoxicillin, which is assumed to conjugate to a carrier present in blood. To standardize the methodology, we propose the use of well-controlled and defined nanomaterials functionalized with amoxicilloyl. Silica nanoparticles decorated with PAMAM-dendrimer-amoxicilloyl conjugates (NpDeAXO) of different sizes and amoxicilloyl densities (50-300 µmol amoxicilloyl/gram nanoparticle) have been prepared and chemically characterized. Two methods of synthesis were performed to ensure reproducibility and stability. Their functional effect on basophils was measured using an

Indexed as

basophil activation testdendrimeric antigensdrug allergy diagnosisPAMAM dendrimerssilica nanoparticles

Identifiers

PMID39204384
PMCPMC11359297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.